Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 4/20 | 0.58 |
| ▸ | PDGFRB | P09619 | 4/20 | 0.58 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.58 |
| ▸ | SRC | P12931 | 1/20 | 0.58 |
| ▸ | RPS6KA3 | P51812 | 1/20 | 0.54 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.53 |
| ▸ | RET | P07949 | 1/20 | 0.53 |
| ▸ | CCNB2 | O95067 | 1/20 | 0.51 |
| ▸ | CDK1 | P06493 | 1/20 | 0.51 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.51 |
| ▸ | CCNB1 | P14635 | 1/20 | 0.51 |
| ▸ | CCR6 | P51684 | 1/20 | 0.51 |
| ▸ | CCNB3 | Q8WWL7 | 1/20 | 0.51 |
| ▸ | PLK4 | O00444 | 1/20 | 0.51 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | MAP4K1 | Q92918 | 1/20 | 0.50 |
| ▸ | MAP1LC3B | Q9GZQ8 | 1/20 | 0.49 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.46 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6389451 | 1.00 | KDR (0.58) | KDRPDGFRBFGFR1SRCRPS6KA3 | |
| SCHEMBL1538367 | 0.85 | KDR (0.59) | KDRPDGFRBFGFR1SRCRPS6KA3 | |
| SCHEMBL2768013 | 0.85 | KDR (0.59) | KDRPDGFRBFGFR1SRCRPS6KA3 | |
| SCHEMBL6390271 | 0.85 | RET (0.62) | KDRPDGFRBFGFR1SRCRPS6KA3 | |
| SCHEMBL6389284 | 0.85 | LRRK2 (0.62) | PDGFRBRPS6KA3SIRT1RETMAP4K1 | |
| SCHEMBL6390272 | 0.85 | RET (0.62) | KDRPDGFRBFGFR1SRCRPS6KA3 | |
| SCHEMBL6389287 | 0.85 | LRRK2 (0.62) | PDGFRBRPS6KA3SIRT1RETMAP4K1 | |
| SCHEMBL6403785 | 0.82 | SIRT1 (0.53) | KDRPDGFRBFGFR1SRCRPS6KA3 | |
| SCHEMBL6395710 | 0.82 | TLK2 (0.64) | KDRPDGFRBFGFR1SRCSIRT1 | |
| SCHEMBL6395714 | 0.82 | TLK2 (0.64) | KDRPDGFRBFGFR1SRCSIRT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | claimed |
| US-6680335-B2 | FOR THERAPY AND PROPHYLAXIS OF CANCER, HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER, PHOBIAS, POST-TRAUMATIC STRESS SYNDROME, AVOIDANT PERSONALITY DISORDER, SEXUAL DYSFUNCTION, EATING DISORDERS, OBESITY | SUGEN, INC. | 2004-01-20 | — | — | US | claimed |
| US-20020183364-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2002-12-05 | — | — | US | claimed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | claimed |
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEM (US) | 2010-11-25 | — | — | US | disclosed |
| US-6878733-B1 | Formulations for pharmaceutical agents ionizable as free acids or free bases | SUGEN, INC. (US) | 2005-04-12 | — | — | US | disclosed |
| US-6855730-B2 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. (US) | 2005-02-15 | — | — | US | disclosed |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | SUGEN, INC. | 2004-02-05 | — | — | US | disclosed |
| US-6680335-B2 | FOR THERAPY AND PROPHYLAXIS OF CANCER, HYPERTENSION, DEPRESSION, GENERALIZED ANXIETY DISORDER, PHOBIAS, POST-TRAUMATIC STRESS SYNDROME, AVOIDANT PERSONALITY DISORDER, SEXUAL DYSFUNCTION, EATING DISORDERS, OBESITY | SUGEN, INC. | 2004-01-20 | — | — | US | disclosed |
| US-6531502-B1 | Antitumor | SUGEN, INC. | 2003-03-11 | — | — | US | disclosed |
| US-20020183364-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | SUGEN, INC. | 2002-12-05 | — | — | US | disclosed |
| WO-2000008202-A9 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN INC (US) | 2000-07-27 | — | — | WO | disclosed |
| WO-2000008202-A2 | 3-METHYLIDENYL-2-INDOLINONE MODULATORS OF PROTEIN KINASE | SUGEN, INC. (US) | 2000-02-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298376-A1 | USE OF NOVEL NEUROPROTECTIVE 3-SUBSTITUTED INDOLONE COMPOSITIONS | NLN, HTT, PARK7 | KDR 3586/4885PDGFRB 2159/4885FGFR1 4427/4885 |
| US-20040024010-A1 | 3-methylidenyl-2-indolinone modulators of protein kinase | DMPK, MAP4K3, MAP3K20 | KDR 1617/4885PDGFRB 1860/4885FGFR1 2701/4885 |
| US-20020183364-A1 | Methods of modulating protein tyrosine kinase function with substituted indolinone compounds | PNCK, CAMK4, CAMK1 | KDR 728/4885PDGFRB 727/4885FGFR1 1066/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.